Increasing Prevalence of Chronic Diseases to Augment the Central Nervous System Biomarkers Market Growth

 

central nervous system biomarkers market

There are many things that can be used to determine the existence of a person's central nervous system. This includes a wide array of medical conditions that can exhibit symptoms such as headaches, migraines, heart palpitations, sweating, back aches, neck pain, numbness, and even more serious conditions such as cardiovascular disease. However, not all of these conditions can produce accurate test results. To this end, there are other tests that can be performed to diagnose someone with central nervous system abnormality.

Central nervous system biomarkers are quantifiable and measurable biological indicators that can be used to diagnose or predict disease, monitor disease progression, and predict treatment response. Biomarkers help understand the development of chronic diseases and identify subjects who are at high risk of developing disease.

Market Dynamics:

Increasing prevalence of chronic diseases, such as Alzheimer’s, is expected to propel the growth of the central nervous system biomarkers market. Alzheimer's disease is the most common form of dementia and may contribute to 60 to 70% of cases. According to the World Health Organization (WHO), around 50 million people worldwide have dementia and there are nearly 10 million new cases every year.

Increasing number of pipeline studies by key players for the development of biomarkers is expected to fuel the growth of the central nervous system biomarkers market. For instance, in Jan 2021, Aptinyx Inc. announced the publication of a recent review article in Medicine in Drug Discovery featuring data on its novel NMDA receptor modulator, NYX-2925. Moreover, the company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease.

The emergence of COVID-19 is expected to offer lucrative growth opportunities for players in the central nervous system biomarkers market. For instance, in Jan. 2021, Mitsubishi Tanabe Pharma America announced revisions to the REFINE-ALS biomarker study protocol to address the safety of people with amyotrophic lateral sclerosis (ALS) during the pandemic.

Competitive Analysis:

Major players operating in the central nervous system biomarkers market are Merc & Co., Applied Neurosolutions, Exonhit Therapeutics, Avacta Group, Avid Radiopharmaceuticals Inc., Banyan Biomarkers, Diagenic ASA, Aposense, Alseres Pharmaceuticals Inc., Apitope International, Adlyfe Inc., Acumen Pharmaceuticals Inc., Abastar MDX Inc., EKF Diagnostics Holdings Inc., Abiant Inc., Enzo Biochem Inc., and Thermo fisher scientific.

In January 2021, Ultragenyx Pharmaceutical announced that the United States Food and Drug Administration (FDA) has cleared the Investigational New Drug application for UX701, an investigational AAV9 gene therapy being evaluated for the treatment of Wilson Disease.

Comments

Popular posts from this blog

Fitness Equipment Market is doing warm-ups to pull growth-rich opportunities from the growing obesity rates accompanied by the sedentary lifestyles

The market for ureteral stents would benefit from the rising prevalence of urological diseases

The North America Vision Care Market Is Driven by the Increasing Prevalence of Eye Diseases in this Region